Dementia Australia welcomes the Therapeutic Goods Administration (TGA) registration of Kisunla (donanemab), for use in Australia, providing hope for people in the early stages of Alzheimer’s disease in the emerging treatments that may delay the progression of symptoms.
Dementia Australia CEO Professor Tanya Buchanan said this drug was an exciting new development and another step forward in the treatment of Alzheimer’s disease.
“With dementia the second leading cause of death of Australians, and the leading cause of death of Australian women, we welcome any steps taken towards improving the lives of people living with dementia, their families and carers,” Professor Buchanan said.
“It is important to note that donanemab does come with possible side effects that needs to be carefully communicated to patients so they can make an informed choice, and the treatment needs to be monitored by health professionals.
“We also need to ensure people understand that donanemab is not a cure and is only suitable for people in the early stages of Alzheimer’s disease with a defined genetic profile – which is why it is so important for people to receive a timely diagnosis.
“We need to raise awareness and understanding of dementia so we can ensure people with concerns about their cognition are seeking information and support as early as possible.
“We know the earlier people access support and services the better their health, care and lifestyle outcomes.”
The drug, developed by pharmaceutical company Eli Lilly, works by inducing antibodies designed to attach to and remove amyloid plaques from the brain.
Dementia Australia Dementia Advocate Peter Duclos, who was recently diagnosed with younger onset Alzheimer’s disease, said the announcement was really positive.
“This announcement provides hope to many people like me who are living with dementia – it provides much excitement now as well as for a future that prolongs time to enjoy with my grandchildren,” Mr Duclos said.
Professor Buchanan reinforced the need for our health systems to be ready for these drugs which require substantial monitoring. She also reinforced the need for investment in dementia research so effective drugs for all forms of dementia can be developed and the progression of dementia can be halted.
“As this and other treatments become available in Australia, we need to ensure that our health systems are ready and to make sure that access to treatment is equitable and available to everyone.
“If this news raises any questions or concerns for anyone about their memory or changes in cognition, please do contact the National Dementia Helpline on 1800 100 500.”
-Ends-
Dementia Australia is the source of trusted information, education and services for the estimated more than 433,300 Australians living with dementia, and the more than 1.7 million people involved in their care. We advocate for positive change and support vital research. We are here to support people impacted by dementia, and to enable them to live as well as possible. No matter how you are impacted by dementia or who you are, we are here for you.
For support, please contact the National Dementia Helpline on 1800 100 500. An interpreter service is available. The National Dementia Helpline is funded by the Australian Government. People looking for information can also visit dementia.org.au
Media contacts: Gabrielle Prabhu, 0447 253 583, [email protected]
When talking or writing about dementia please refer to Dementia-Friendly Language Guidelines.
Note to Editors:
We request, where possible, details for the National Dementia Helpline 1800 100 500 appear alongside news stories about dementia, as these stories often prompt questions or concerns:
If this story has prompted any questions or concerns, please call the National Dementia Helpline 1800 100 500 (24 hours, 7 days a week) or visit dementia.org.au.
